Based on these data, it appears that the depletion of SNORD50A/B often found in patient tumor samples is a key step for lung tumor initiation by activating the oncogenic KRas pathway, the genomic alterations of which represent about 25% of lung adenocarcinomas [42]. This evidence concerns the gene KRAS and neoplasm.